Celecoxib and cisplatin dual-loaded microspheres synergistically enhance transarterial chemoembolization effect of hepatocellular carcinoma

Kunpeng Wu; Shengnan Ma; Xiaohong Xu; Yiming Liu; Chuan Tian; Chengzhi Zhang; Jiheng Shan; Zongming Li; Kewei Ren; Jianzhuang Ren; Xinwei Han; Yanan Zhao

Materials Today Bio (Feb 2024)

Celecoxib and cisplatin dual-loaded microspheres synergistically enhance transarterial chemoembolization effect of hepatocellular carcinoma

Kunpeng Wu,
Shengnan Ma,
Xiaohong Xu,
Yiming Liu,
Chuan Tian,
Chengzhi Zhang,
Jiheng Shan,
Zongming Li,
Kewei Ren,
Jianzhuang Ren,
Xinwei Han,
Yanan Zhao

Affiliations

Kunpeng Wu: Department of Interventional Radiology, Key Laboratory of Interventional Radiology of Henan Province, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China; Interventional Institute of Zhengzhou University, Zhengzhou, 450052, China; Interventional Treatment and Clinical Research Center of Henan Province, Zhengzhou, 450052, China
Shengnan Ma: Department of Endocrinology and Metabolism, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, 450052, Henan, China; Corresponding author. Department of Endocrinology and Metabolism, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, 450052, Henan, China.
Xiaohong Xu: Department of Interventional Radiology, Key Laboratory of Interventional Radiology of Henan Province, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China; Interventional Institute of Zhengzhou University, Zhengzhou, 450052, China; Interventional Treatment and Clinical Research Center of Henan Province, Zhengzhou, 450052, China
Yiming Liu: Department of Interventional Radiology, Key Laboratory of Interventional Radiology of Henan Province, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China; Interventional Institute of Zhengzhou University, Zhengzhou, 450052, China; Interventional Treatment and Clinical Research Center of Henan Province, Zhengzhou, 450052, China
Chuan Tian: Department of Interventional Medical Center, the Affiliated Hospital of Qingdao University, No. 1677 Wutaishan Road, Shandong, 266000, Qingdao, China
Chengzhi Zhang: Department of Interventional Radiology, Key Laboratory of Interventional Radiology of Henan Province, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China; Interventional Institute of Zhengzhou University, Zhengzhou, 450052, China; Interventional Treatment and Clinical Research Center of Henan Province, Zhengzhou, 450052, China
Jiheng Shan: Department of Interventional Radiology, Key Laboratory of Interventional Radiology of Henan Province, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China; Interventional Institute of Zhengzhou University, Zhengzhou, 450052, China; Interventional Treatment and Clinical Research Center of Henan Province, Zhengzhou, 450052, China
Zongming Li: Department of Interventional Radiology, Key Laboratory of Interventional Radiology of Henan Province, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China; Interventional Institute of Zhengzhou University, Zhengzhou, 450052, China; Interventional Treatment and Clinical Research Center of Henan Province, Zhengzhou, 450052, China
Kewei Ren: Department of Interventional Radiology, Key Laboratory of Interventional Radiology of Henan Province, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China; Interventional Institute of Zhengzhou University, Zhengzhou, 450052, China; Interventional Treatment and Clinical Research Center of Henan Province, Zhengzhou, 450052, China
Jianzhuang Ren: Department of Interventional Radiology, Key Laboratory of Interventional Radiology of Henan Province, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China; Interventional Institute of Zhengzhou University, Zhengzhou, 450052, China; Interventional Treatment and Clinical Research Center of Henan Province, Zhengzhou, 450052, China; Corresponding author. Department of Interventional Radiology, Key Laboratory of Interventional Radiology of Henan Province, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.
Xinwei Han: Department of Interventional Radiology, Key Laboratory of Interventional Radiology of Henan Province, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China; Interventional Institute of Zhengzhou University, Zhengzhou, 450052, China; Interventional Treatment and Clinical Research Center of Henan Province, Zhengzhou, 450052, China; Corresponding author. Department of Interventional Radiology, Key Laboratory of Interventional Radiology of Henan Province, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.
Yanan Zhao: Department of Interventional Radiology, Key Laboratory of Interventional Radiology of Henan Province, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China; Interventional Institute of Zhengzhou University, Zhengzhou, 450052, China; Interventional Treatment and Clinical Research Center of Henan Province, Zhengzhou, 450052, China; Corresponding author. Department of Interventional Radiology, Key Laboratory of Interventional Radiology of Henan Province, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.

Journal volume & issue: Vol. 24
p. 100927

Abstract

Read online

Transarterial chemoembolization (TACE) is a first-line treatment for intermediate to advanced-stage liver cancer, with drug-eluting microspheres commonly used as embolic agents. However, currently available drug-eluting microspheres suffer from low drug-loading capacity and limited drug options. In this work, we developed polydopamine-modified polyvinyl alcohol dual-drug-loaded microspheres encapsulating celecoxib and cisplatin (referred to as PCDMS). Physicochemical characterization revealed that the surface of the microspheres displayed increased roughness after polydopamine modification, and celecoxib and cisplatin were successfully loaded onto the microsphere surface. In vitro cell experiments demonstrated that the PCDMS significantly inhibited the proliferation and migration of highly metastatic human liver cancer cells (MHCC-97H) and human liver cancer cells (SMMC-7721). Furthermore, the dual-loaded microspheres exhibited remarkable tumor growth inhibition and reshaped the tumor microenvironment in both subcutaneous H22 liver cancer model in Balb/c mice and intrahepatic VX2 tumor model in New Zealand rabbits, demonstrating a synergistic antitumor effect where 1 + 1>2. This work provides a potential therapeutic approach for the treatment of refractory liver cancer and holds significant translational potential.

Published in Materials Today Bio

ISSN: 2590-0064 (Online)
Publisher: Elsevier
Country of publisher: Netherlands
LCC subjects: Medicine: Medicine (General); Science: Biology (General)
Website: https://www.journals.elsevier.com/materials-today-bio

About the journal

Abstract

Keywords